AMCP Submits Comments to HHS OIG on Proposed Revisions to AKS Safe Harbors; AMCP to Comment on White House Proposal to Allow Drug Importation; FDA Issues Draft Guidance on Interchangeable Insulin; AMCP Invited to Participate in Pharmaceutical Quality Workshop

Trump Administration Issues Proposed Rule Allowing Importation; House Passes H.R. 3 Drug Pricing Bill on Party-Line Vote; AMCP Submits Letter to House on 21st Century Cures 2.0; Stephen Hahn, MD, Confirmed as New FDA Commissioner; FDA Issues Draft Guidance on Interchangeable Insulin

AMCP Joins Stakeholder Letter to SAMHSA on Proposed Rule to Update 42 CFR Part 2; AMCP Seeks Input on Proposed Rule to Change Anti-Kickback Statute; CMS Issues Price Transparency Rules
for Hospital and Insurers

HHS OIG Issues Proposed Rule to Remove Regulatory Barriers to Care Coordination, Value-based Care; Congress Continues Work on Drug Pricing Bills in House and Senate;

House Speaker Nancy Pelosi Introduces Drug Pricing Bill H.R.3; Hill Days: AMCP Takes Message to
House and Senate Offices; SAMHSA Issues New Proposed Rule to Modernize 42 CFR Part 2

AMCP Submits Comments to Senate Finance Committee on Drug Pricing Bill HHS Announces Action Plan for Safe Importation of Prescription Drugs; CMS Issues 2020 Physician Fee Schedule; AMCP Submits Comments on Reducing Administrative Burdens in Health Care

White House Withdraws ‘Rebate Rule’; House Holds Hearings and Markups on Bills Addressing Drug Pricing Transparency; CMS Issues New Proposed Rule on ePA; CMS Seeks Comments on Reducing Administrative Burdens in Health Care AMCP Takes Steps to Improve Prior Authorization on Processes